LivaNova PLC

DB:LIA Stock Report

Market Cap: €2.7b

LivaNova Valuation

Is LIA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of LIA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: LIA (€48.2) is trading below our estimate of fair value (€75.42)

Significantly Below Fair Value: LIA is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LIA?

Key metric: As LIA is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for LIA. This is calculated by dividing LIA's market cap by their current earnings.
What is LIA's PE Ratio?
PE Ratio117.7x
EarningsUS$23.68m
Market CapUS$2.81b

Price to Earnings Ratio vs Peers

How does LIA's PE Ratio compare to its peers?

The above table shows the PE ratio for LIA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average21.7x
AFX Carl Zeiss Meditec
24.4x16.3%€5.0b
DRW3 Drägerwerk KGaA
7.2x2.0%€796.1m
EUZ Eckert & Ziegler
23.2x5.9%€831.3m
SBS Stratec
32.1x25.4%€321.5m
LIA LivaNova
117.7x48.1%€2.8b

Price-To-Earnings vs Peers: LIA is expensive based on its Price-To-Earnings Ratio (117.7x) compared to the peer average (21.7x).

Price to Earnings Ratio vs Industry

How does LIA's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
LIA 117.7xIndustry Avg. 29.5xNo. of Companies7PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: LIA is expensive based on its Price-To-Earnings Ratio (117.7x) compared to the European Medical Equipment industry average (28.2x).

Price to Earnings Ratio vs Fair Ratio

What is LIA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LIA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio117.7x
Fair PE Ratio46.8x

Price-To-Earnings vs Fair Ratio: LIA is expensive based on its Price-To-Earnings Ratio (117.7x) compared to the estimated Fair Price-To-Earnings Ratio (46.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst LIA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€48.20
€65.47
+35.8%
13.6%€85.39€50.29n/a11
Nov ’25€46.60
€63.44
+36.1%
13.6%€82.75€48.73n/a11
Oct ’25€46.40
€62.98
+35.7%
14.6%€80.97€47.68n/a10
Sep ’25€46.20
€63.85
+38.2%
16.2%€83.40€49.12n/a10
Aug ’25€45.00
€63.85
+41.9%
16.2%€83.40€49.12n/a10
Jul ’25€50.00
€64.10
+28.2%
14.4%€82.76€48.74n/a10
Jun ’25€55.50
€64.51
+16.2%
15.4%€83.90€49.41n/a10
May ’25€51.50
€63.04
+22.4%
15.9%€84.18€49.57n/a10
Apr ’25€51.00
€61.37
+20.3%
13.3%€75.67€48.91n/a10
Mar ’25€50.00
€61.37
+22.7%
13.3%€75.67€48.91n/a10
Feb ’25€44.40
€55.26
+24.5%
14.9%€74.53€42.72n/a10
Jan ’25€46.80
€55.26
+18.1%
14.9%€74.53€42.72n/a10
Dec ’24€40.40
€57.44
+42.2%
13.8%€77.21€49.90n/a10
Nov ’24€45.60
€58.48
+28.2%
14.2%€77.60€49.21€46.6010
Oct ’24€50.00
€60.43
+20.9%
13.6%€77.42€49.10€46.4010
Sep ’24€50.50
€60.22
+19.2%
12.5%€75.58€48.85€46.209
Aug ’24€52.50
€59.57
+13.5%
12.5%€74.77€48.33€45.009
Jul ’24€46.40
€55.10
+18.8%
16.3%€72.71€43.63€50.008
Jun ’24€40.80
€55.10
+35.1%
16.3%€72.71€43.63€55.508
May ’24€42.60
€56.60
+32.9%
19.6%€72.74€40.91€51.508
Apr ’24€38.60
€63.87
+65.5%
11.2%€75.46€56.59€51.007
Mar ’24€44.00
€63.87
+45.2%
11.2%€75.46€56.59€50.007
Feb ’24€51.00
€68.02
+33.4%
11.5%€79.20€56.57€44.407
Jan ’24€51.50
€66.89
+29.9%
11.7%€79.14€56.53€46.808
Dec ’23€52.50
€70.15
+33.6%
11.2%€81.52€58.23€40.407
Nov ’23€47.00
€81.96
+74.4%
10.3%€96.82€72.10€45.607

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

LNA Santé

€244.4m

Engages in the management and operation of health establishments.

2N3

€23.25

7D

-6.1%

1Y

16.0%

Shandong Weigao Group Medical Polymer

HK$20.1b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.52

7D

-1.0%

1Y

-38.8%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

7D

0.5%

1Y

-82.5%